Horizon Therapeutics Public Limited Company ( HZNP Quick Quote HZNP - Free Report) rose 13.29% after it reported fourth-quarter 2020 adjusted earnings of $1.28 per share, which increased from the year-ago quarterly earnings of 56 cents. The earnings also beat the Zacks Consensus Estimate of $1.05 per share.
Quarterly sales of $745.3 million were up 105% year over year. The top line also beat the Zacks Consensus Estimate of $694 million. Sales were driven by the strong launch of Tepezza.
Horizon Therapeutics’ share price has skyrocketed 181.8% year to date compared with the
industry’s growth of 13.5%. Quarter in Detail
The company reports financial results under two segments — Orphan and Rheumatology, and Inflammation (previously known as the primary care segment). Notably, first-quarter 2020 onward, the Orphan and Rheumatology segment was renamed the Orphan segment.
Sales in the Orphan segment were $628.2 million, up 151% from the prior-year figure, driven by the continued growth of drugs like Tepezza, Krystexxa, Procysbi and Actimmune.The segment represented 84% of total fourth-quarter net sales.
Krystexxa sales increased 16% year over year to $128.9 million. Tepezza generated net sales worth $343.3 million in the fourth quarter. In January 2020, the FDA approved Tepezza for the treatment of thyroid eye disease (TED).
Ravicti sales were $70.2 million in the quarter, up 3% year over year.
Fourth-quarter 2020 net sales in the Inflammation segment were $117.1 million, up 3% year over year.
Adjusted research and development expenses were $38.3 million, up from $26.5 million in the year-ago quarter. Adjusted SG&A expenses were $240.6 million, up from $161.1 million in the year-ago quarter.
Full-Year 2020 Results
The company reported adjusted earnings of $3.88 per share in 2020, up from $1.94 in 2019. Earnings beat the Zacks Consensus Estimate of $3.64 per share.
Sales came in at $2.20 billion in 2020, which increased from $1.30 billion in 2019 and beat the Zacks Consensus Estimate of $2.15 billion.
The company expects 2021 net sales between $2.70 billion and $2.80 billion, indicating 25% growth at the midpoint. THE Zacks Consensus Estimate stands at $2.74 billion. The company expects Tepezza net sales to be greater than $1.275 billion and Krystexxa net sales to be above $500 million.
Other Pipeline Updates
In January 2021, the company submitted a prior approval supplement to the FDA to support increased scale production of the Tepezza drug product for the treatment of Thyroid TED.
The company expects to initiate a randomized, placebo-controlled trial of Tepezza in patients with chronic TED in the second quarter of 2021, assuming a normalized supply of the drug.
On Jan 31, 2021, the company entered into a definitive agreement to acquire Viela, a biotechnology company with a deep, mid-stage biologics pipeline for autoimmune and severe inflammatory diseases and Uplizna, a recently approved biologic medicine for a rare disease.. The company will acquire all of Viela’s common stock for $53 per share in cash, which represents an equity value of about $2.67 billion.
Zacks Rank and Stocks to Consider
Horizon currently carries a Zacks Rank #5 (Strong Sell).
Some better-ranked stocks in the healthcare sector include
Acorda Therapeutics Inc. ( ACOR Quick Quote ACOR - Free Report) , Atea Pharmaceuticals Inc. ( AVIR Quick Quote AVIR - Free Report) and Clearside Biomedical Inc. ( CLSD Quick Quote CLSD - Free Report) . All of them carry a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here .
Acorda’s loss per share estimates have narrowed from $9.66 to $7.91 for 2020 over the past 60 days.
Atea’s earnings per share estimates have increased from $3.53 to $3.70 for 2021 over the past 60 days. Shares of the company have increased 163.6% in the past year.
Clearside’s loss per share estimates have narrowed from 38 cents to 28 cents for 2021 over the past 60 days. Shares of the company have increased 36.1% in the past year.
More Stock News: This Is Bigger than the iPhone!
It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 77 billion devices by 2025, creating a $1.3 trillion market. Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 4 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2022.
Click here for the 4 trades >>